This video is sponsored by the Duke Clinical Medical Series.
* Clinical Case
* Medical History
* Laboratory Values
* Physical Examination
* The CHARISMA Trial: Implications for Clinical Practice
* CAPRIE: Superior Efficacy of Clopidogrel vs ASA
* CAPRIE: Clopidogrel Reduced Rate of Rehosp
* Clopidogrel: Amplified Benefit Patients with High Vascular Risk
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
The guest, Deepak Bhatt, MD, has indicated that he is a consultant for Astra Zeneca,
Bristol-Myers Squibb, Eli Lilly, Millenium, Schering Plough, Sanofi Aventis, The Medicines